{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT07148557",
      "orgStudyIdInfo": {
        "id": "P10-LP003-09"
      },
      "organization": {
        "fullName": "Longbio Pharma",
        "class": "INDUSTRY"
      },
      "briefTitle": "A Study of Single Dose of LP-003 in Adolescent Subjects",
      "officialTitle": "A Single-center, Open-label, Phase Ib Clinical Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Characteristics of LP-003 Injection in Adolescent Subjects Aged 12-18 Years"
    },
    "statusModule": {
      "statusVerifiedDate": "2025-08",
      "overallStatus": "NOT_YET_RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2025-08-31",
        "type": "ESTIMATED"
      },
      "primaryCompletionDateStruct": {
        "date": "2026-05-31",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2026-09-30",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2025-08-15",
      "studyFirstSubmitQcDate": "2025-08-22",
      "studyFirstPostDateStruct": {
        "date": "2025-08-29",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2025-08-22",
      "lastUpdatePostDateStruct": {
        "date": "2025-08-29",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Longbio Pharma",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false,
      "isUsExport": false
    },
    "descriptionModule": {
      "briefSummary": "This is a single-center, open-label, phase Ib clinical study to evaluate the safety, pharmacokinetics and pharmacodynamic characteristics of LP-003 injection in adolescent subjects aged 12-18 years."
    },
    "conditionsModule": {
      "conditions": [
        "Chronic Spontaneous Urticaria (CSU)",
        "Seasonal Allergic Rhinitis (SAR)"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "SEQUENTIAL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 6,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Cohort 1: LP-003 Dose 1 (Single)",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: LP-003 Dose 1 (Single)"
          ]
        },
        {
          "label": "Cohort 2 : LP-003 Dose 2 (Single)",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: LP-003 Dose 2 (Single)"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "LP-003 Dose 1 (Single)",
          "description": "A single dose of LP-003 (400 mg/dose) was SC",
          "armGroupLabels": [
            "Cohort 1: LP-003 Dose 1 (Single)"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "LP-003 Dose 2 (Single)",
          "description": "A single dose of LP-003 (600 mg/dose) was SC",
          "armGroupLabels": [
            "Cohort 2 : LP-003 Dose 2 (Single)"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Adverse Events (AE)",
          "description": "Number of subjects with treatment-related Treatment Emergent Adverse Events (TEAEs).",
          "timeFrame": "Observation for 196 days after administration"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Time to peak concentration (Tmax) of LP-003",
          "description": "The time when the blood drug concentration reaches its peak after a single dose of medication.",
          "timeFrame": "Observation for 196 days after administration"
        },
        {
          "measure": "Maximum concentration (Cmax) of LP-003",
          "description": "The maximum concentration of LP-003 in the bloodstream after administration.",
          "timeFrame": "Observation for 196 days after administration"
        },
        {
          "measure": "Elimination half-life (t1/2) of LP-003",
          "description": "The time required for the concentration of LP-003 in the bloodstream to decrease by half.",
          "timeFrame": "Observation for 196 days after administration"
        },
        {
          "measure": "Area under the concentration-time curve (AUC0-t) of LP-003",
          "description": "The area under the concentration-time curve (AUC) from time zero to the last chosen time point represents the integral of the drug concentration in the bloodstream over the specified duration.",
          "timeFrame": "Observation for 196 days after administration"
        },
        {
          "measure": "Apparent clearance rate (CL/F) of LP-003",
          "description": "The ratio of drug clearance to drug concentration, represents the apparent clearance of a drug after administration, adjusted for bioavailability.",
          "timeFrame": "Observation for 196 days after administration"
        },
        {
          "measure": "Assessment of total immunoglobulin E (IgE)",
          "description": "The changes in serum total IgE levels compared to baseline at different assessment time points.",
          "timeFrame": "Observation for 196 days after administration"
        },
        {
          "measure": "Assessment of free immunoglobulin E (IgE)",
          "description": "The changes in serum free IgE levels compared to baseline at different assessment time points.",
          "timeFrame": "Observation for 196 days after administration"
        },
        {
          "measure": "Assessment of immunogenicity",
          "description": "The proportion of anti drug antibody (ADA) positive subjects at different detection time points.",
          "timeFrame": "Observation for 196 days after administration"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Adolescent subjects aged ≥12 years and \\<18 years, male or female.\n* History of allergic diseases (self-reported is acceptable), including, but not limited to, food allergies, allergic rhinitis, allergic asthma, urticaria, and atopic dermatitis.\n* Agreement to use effective contraception during the study and for 6 months after the end of the study.\n* Subject and parent or legal guardian able to understand and voluntarily sign the informed consent form, and comply with study visits and related procedures.\n\nExclusion Criteria:\n\n* Allergic to LP-003 or its excipients.\n* Any serious or uncontrolled chronic disease (e.g., severe arrhythmia, ischemic heart disease, NYHA Class III/IV heart failure, severe pulmonary disease, inadequately controlled asthma, hypertension, diabetes, hypo- or hyperthyroidism) that may affect subject safety as determined by the Investigator.\n* History of severe allergic reactions.\n* Abnormal venous access, venipuncture or subcutaneous injection intolerance, history of needle or blood phobia.\n* Estimated glomerular filtration rate (eGFR) \\<30 mL/min/1.73m² at screening.\n* ALT or AST \\> ULN and considered clinically significant by the Investigator.\n* Any other abnormal screening test result that, in the Investigator's opinion, could affect subject safety or study assessments.\n* Systemic corticosteroid therapy (intravenous, intramuscular, or oral) within 4 weeks prior to study drug administration.\n* Use of medications known to interact with epinephrine (e.g., β-blockers, ACE inhibitors, tricyclic antidepressants) within 4 weeks prior to administration.\n* Use of biologic products (e.g., omalizumab) within 6 months prior to administration.\n* Receipt vaccines within 14 days before administration or planning vaccination during the study.\n* Participation in other clinical trials within 3 months prior to screening or within 5 half-lives of investigational product discontinuation (whichever is longer).\n* Any other conditions that the Investigator considers subjects unsuitable for participation in the study.",
      "healthyVolunteers": true,
      "sex": "ALL",
      "minimumAge": "12 Years",
      "maximumAge": "18 Years",
      "stdAges": [
        "CHILD",
        "ADULT"
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D000080223",
          "term": "Chronic Urticaria"
        },
        {
          "id": "D006255",
          "term": "Rhinitis, Allergic, Seasonal"
        }
      ],
      "ancestors": [
        {
          "id": "D014581",
          "term": "Urticaria"
        },
        {
          "id": "D017445",
          "term": "Skin Diseases, Vascular"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        },
        {
          "id": "D002908",
          "term": "Chronic Disease"
        },
        {
          "id": "D020969",
          "term": "Disease Attributes"
        },
        {
          "id": "D010335",
          "term": "Pathologic Processes"
        },
        {
          "id": "D013568",
          "term": "Pathological Conditions, Signs and Symptoms"
        },
        {
          "id": "D065631",
          "term": "Rhinitis, Allergic"
        },
        {
          "id": "D012220",
          "term": "Rhinitis"
        },
        {
          "id": "D009668",
          "term": "Nose Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D012130",
          "term": "Respiratory Hypersensitivity"
        },
        {
          "id": "D010038",
          "term": "Otorhinolaryngologic Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D012847",
          "term": "Single Person"
        }
      ],
      "ancestors": [
        {
          "id": "D017533",
          "term": "Marital Status"
        },
        {
          "id": "D005191",
          "term": "Family Characteristics"
        },
        {
          "id": "D003710",
          "term": "Demography"
        },
        {
          "id": "D011154",
          "term": "Population Characteristics"
        },
        {
          "id": "D012959",
          "term": "Socioeconomic Factors"
        }
      ]
    }
  },
  "hasResults": false
}